NaviGate touts implantation for Gate transcath tricuspid valve replacement

NaviGate Cardiac Structures Inc. said today that earlier this month, its catheter-guided Gate valved-stent bioprosthesis became the first orthotopic valve replacement in Canada to treat severe tricuspid regurgitation.

The implantation was done at the Quebec Heart and Lung Institute, lead by interventional cardiologists Dr. Josep Rodes-Cabau and Dr. Francois Dagenais.

The 79-year-old male patient who received the implant had severe symptomatic tricuspid regurgitation and was not eligible for standard cardiac surgery, according to NaviGate.

“The NaviGate bioprosthesis is the only transcatheter device in development that has been used to completely replace the native tricuspid valve and restore its function in the human,” Dr. Rodes-Cabau said in prepared remarks.

After the patient was prepared, the replacement procedure took less than 30 minutes, NaviGate touted, and the patient was discharged within a few days.

“We see these patients continuously, showing edema of their lower limbs, shortness of breath and their chests full of liquid,” cardiologist Dr. Elisabeth Bedard added. “We give them medications to relieve them of some fluid but in a short time come to an end where we cannot help them anymore. Suddenly, we see a superb new technology that may help our patients.”

“NaviGate Cardiac Structures Inc. is very pleased to have helped the Canadian patient by correction of tricuspid regurgitation,” Dr. R. C. Quijano, NaviGate’s president & CEO, said. “Canada is now another country where NCSI has a patient whose severe-to-torrential TR conditions was treated by the bioprosthesis, and it happened at the most progressive research center in the country.”

The post NaviGate touts implantation for Gate transcath tricuspid valve replacement appeared first on MassDevice.

from MassDevice http://ift.tt/2BJ9ABR